Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? [Yahoo! Finance]
Alkermes plc - Ordinary Shares (ALKS)
Last alkermes plc - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-irhome
Company Research
Source: Yahoo! Finance
Lybalvi (schizophrenia and bipolar I disorder), which are witnessing a steady uptake and driving growth. Alkermes' set of proprietary products has generated combined sales worth $1.08 billion in 2024, reflecting an increase of 18% on a year-over-year basis. The company expects to record $1.09-$1.15 billion in revenues from proprietary products in 2025. The alcohol dependence treatment market has driven new patients toward Vivitrol while Aristada continues to generate steady sales. Net sales for Vivitrol are expected to be in the range of $440-$460 million, while Aristada sales are anticipated in the band of $335-$355 million in 2025. Lybalvi (olanzapine and samidorphan), too, has been witnessing strong sales uptake. The company expects to generate sales between $320 million and $340 million in 2025 from Lybalvi. Shares of Alkermes have rallied 20.9% year to date compared with the industry's increase of 6%. Image Source: Zacks Investment Research Alkermes is developing ALKS
Show less
Read more
Impact Snapshot
Event Time:
ALKS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALKS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALKS alerts
High impacting Alkermes plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ALKS
News
- Alkermes (NASDAQ:ALKS) had its "buy (b-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Alkermes (NASDAQ:ALKS) had its "buy (b-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Trends and Market Growth Opportunities in the Alcohol Use Disorder Industry, 2025-2032 [Yahoo! Finance]Yahoo! Finance
- Alkermes (NASDAQ:ALKS) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "hold (c+)" rating to a "buy (b-)" rating.MarketBeat
- Alkermes to Participate in Two Upcoming Investor ConferencesBusiness Wire
ALKS
Earnings
- 10/28/25 - Beat
ALKS
Sec Filings
- 12/5/25 - Form 4
- 12/3/25 - Form 144
- 12/1/25 - Form 4
- ALKS's page on the SEC website